elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q38857067-6B08564F-83F2-477A-AF0F-863D8DE47D28
Q38857067-6B08564F-83F2-477A-AF0F-863D8DE47D28
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38857067-6B08564F-83F2-477A-AF0F-863D8DE47D28
Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML.
P2860
Q38857067-6B08564F-83F2-477A-AF0F-863D8DE47D28
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38857067-6B08564F-83F2-477A-AF0F-863D8DE47D28
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
0e2959faebb7de532c51a672e0c1e2e28e00df8d
P2860
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.